Skip to Main Content

Author Details

Craig B Wilen
Yale School of Medicine
2010
106
43
Wade Schulz (CM4AI)
PMIDPaper TitleJournal TitlePublished Year
36894709Pharmacological disruption of mSWI/SNF complex activity restricts SARS-CoV-2 infection.Nat Genet2023
37808797Survey of white-footed mice in Connecticut, USA reveals low SARS-CoV-2 seroprevalence and infection with divergent betacoronaviruses.bioRxiv2023
37808733Genome-wide CRISPR activation screen identifies JADE3 as an antiviral activator of NF-kB.bioRxiv2023
37703370IFN-λ derived from nonsusceptible enterocytes acts on tuft cells to limit persistent norovirus.Sci Adv2023
37693555Differences in syncytia formation by SARS-CoV-2 variants modify host chromatin accessibility and cellular senescence via TP53.bioRxiv2023
37991919Differences in syncytia formation by SARS-CoV-2 variants modify host chromatin accessibility and cellular senescence via TP53.Cell Rep2023
37541244Mammalian SWI/SNF chromatin remodeling complexes promote tyrosine kinase inhibitor resistance in EGFR-mutant lung cancer.Cancer Cell2023
37188813Age-associated features of norovirus infection analysed in mice.Nat Microbiol2023
37410700The KDM6A-KMT2D-p300 axis regulates susceptibility to diverse coronaviruses by mediating viral receptor expression.PLoS Pathog2023
37310920DYRK1A promotes viral entry of highly pathogenic human coronaviruses in a kinase-independent manner.PLoS Biol2023
37276355Game over for RSV?Sci Immunol2023
36974986Nonsystematic Reporting Biases of the SARS-CoV-2 Variant Mu Could Impact Our Understanding of the Epidemiological Dynamics of Emerging Variants.Genome Biol Evol2023
37438530PLSCR1 is a cell-autonomous defence factor against SARS-CoV-2 infection.Nature2023
37478303Murine Norovirus: Additional Protocols for Basic and Antiviral Studies.Curr Protoc2023
37296103Systematic detection of tertiary structural modules in large RNAs and RNP interfaces by Tb-seq.Nat Commun2023
34757384A stem-loop RNA RIG-I agonist protects against acute and chronic SARS-CoV-2 infection in mice.J Exp Med2022
35378749Insights into the limited global spread of the immune evasive SARS-CoV-2 variant Mu.medRxiv2022
35347138Monospecific and bispecific monoclonal SARS-CoV-2 neutralizing antibodies that maintain potency against B.1.617.Nat Commun2022
35668119Omicron-specific mRNA vaccination alone and as a heterologous booster against SARS-CoV-2.Nat Commun2022
35853867Heterotypic vaccination responses against SARS-CoV-2 Omicron BA.2.Cell Discov2022
35561673Variant-specific vaccination induces systems immune responses and potent in vivo protection against SARS-CoV-2.Cell Rep Med2022
35713752Defining Clinical and Immunological Predictors of Poor Immune Responses to COVID-19 mRNA Vaccines in Patients with Primary Antibody Deficiency.J Clin Immunol2022
35483404Inflammasome activation in infected macrophages drives COVID-19 pathology.Nature2022
36550362Plasmodium infection is associated with cross-reactive antibodies to carbohydrate epitopes on the SARS-CoV-2 Spike protein.Sci Rep2022
36228039LRRC15 inhibits SARS-CoV-2 cellular entry in trans.PLoS Biol2022
36351394Tuft-cell-intrinsic and -extrinsic mediators of norovirus tropism regulate viral immunity.Cell Rep2022
36165196Coronavirus Lung Infection Impairs Host Immunity against Secondary Bacterial Infection by Promoting Lysosomal Dysfunction.J Immunol2022
35921835Multiplexed LNP-mRNA vaccination against pathogenic coronavirus species.Cell Rep2022
35879412Genome-wide bidirectional CRISPR screens identify mucins as host factors modulating SARS-CoV-2 infection.Nat Genet2022
34921308A humanized mouse model of chronic COVID-19.Nat Biotechnol2022
34914544High-affinity, neutralizing antibodies to SARS-CoV-2 can be made without T follicular helper cells.Sci Immunol2022
35271673Tuft cells are key mediators of interkingdom interactions at mucosal barrier surfaces.PLoS Pathog2022
35301314De novo emergence of a remdesivir resistance mutation during treatment of persistent SARS-CoV-2 infection in an immunocompromised patient: a case report.Nat Commun2022
35263388Reovirus infection is regulated by NPC1 and endosomal cholesterol homeostasis.PLoS Pathog2022
35107369Restriction of Viral Replication, Rather than T Cell Immunopathology, Drives Lethality in Murine Norovirus CR6-Infected STAT1-Deficient Mice.J Virol2022
35194606Omicron-specific mRNA vaccination alone and as a heterologous booster against SARS-CoV-2.bioRxiv2022
34705554Distinct Roles of Type I and Type III Interferons during a Native Murine β Coronavirus Lung Infection.J Virol2022
34611663Inflammasome activation in infected macrophages drives COVID-19 pathology.bioRxiv2022
33147444Genome-wide CRISPR Screens Reveal Host Factors Critical for SARS-CoV-2 Infection.Cell2021
33758831A humanized mouse model of chronic COVID-19 to evaluate disease mechanisms and treatment options.Res Sq2021
33730024Single-cell longitudinal analysis of SARS-CoV-2 infection in human airway epithelium identifies target cells, alterations in gene expression, and cell state changes.PLoS Biol2021
33705489Norovirus evolution in immunodeficient mice reveals potentiated pathogenicity via a single nucleotide change in the viral capsid.PLoS Pathog2021
33754989Stability of SARS-CoV-2 RNA in Nonsupplemented Saliva.Emerg Infect Dis2021
34981065Monospecific and bispecific monoclonal SARS-CoV-2 neutralizing antibodies that maintain potency against B.1.617.bioRxiv2021
34909781<i>De novo</i> emergence of a remdesivir resistance mutation during treatment of persistent SARS-CoV-2 infection in an immunocompromised patient: A case report.medRxiv2021
34453881Live imaging of SARS-CoV-2 infection in mice reveals that neutralizing antibodies require Fc function for optimal efficacy.Immunity2021
34845449LRRC15 is an inhibitory receptor blocking SARS-CoV-2 spike-mediated entry <i>in trans</i>.bioRxiv2021
34045361Translational shutdown and evasion of the innate immune response by SARS-CoV-2 NSP14 protein.Proc Natl Acad Sci U S A2021
34185680Restriction of SARS-CoV-2 replication by targeting programmed -1 ribosomal frameshifting.Proc Natl Acad Sci U S A2021
34159330A stem-loop RNA RIG-I agonist confers prophylactic and therapeutic protection against acute and chronic SARS-CoV-2 infection in mice.bioRxiv2021
  • 1 - 50 of 106

Recommended Authors

James Logue
Center for Pathogen Research, University of Maryland School of Medicine
Career Start Year 2017
Number of shared co-authors 5
Aminu S Jahun
University of Cambridge, Addenbrooke's Hospital Level 5
Career Start Year 2017
Number of shared co-authors 3
Mir M Khalid
Gladstone Institutes
Career Start Year 2016
Number of shared co-authors 6
Camille R Simoneau
Gladstone Institute of Virology
Career Start Year 2015
Number of shared co-authors 11
Stuart Weston
University of Maryland School of Medicine
Career Start Year 2014
Number of shared co-authors 7
David Sachs
Icahn School of Medicine at Mount Sinai
Career Start Year 2013
Number of shared co-authors 4
R??my Robinot
Institut Pasteur, Universite Paris Cite, CNRS UMR 9
Career Start Year 2012
Number of shared co-authors 2
Shashank Tripathi
Indian Institute of Science
Career Start Year 2011
Number of shared co-authors 5
Jennifer Tisoncik-Go
Center for Innate Immunity and Immune Disease, University of Washington
Career Start Year 2009
Number of shared co-authors 5
Siyuan Ding
Washington University School of Medicine
Career Start Year 2009
Number of shared co-authors 7
Vineet D Menachery
University of Texas Medical Branch
Career Start Year 2008
Number of shared co-authors 6
Judd F Hultquist
Northwestern University Feinberg School of Medicine
Career Start Year 2008
Number of shared co-authors 6
Hans-Heinrich Hoffmann
The Rockefeller University
Career Start Year 2008
Number of shared co-authors 6
Mohsan Saeed
Boston University Chobanian and Avedisian School of Medicine
Career Start Year 2007
Number of shared co-authors 2
Stephanie A Montgomery
and Lineberger Comprehensive Cancer Center, University of North Carolina System
Career Start Year 2006
Number of shared co-authors 5
Sudhakar Agnihothram
National Center for Toxicological Research
Career Start Year 2005
Number of shared co-authors 4
Yaw Shin Ooi
Duke-NUS Medical School
Career Start Year 2003
Number of shared co-authors 5
Lisa E Gralinski
University of North Carolina at Chapel Hill
Career Start Year 2002
Number of shared co-authors 4
Luis Martinez-Sobrido
Texas Biomedical Research Institute
Career Start Year 2001
Number of shared co-authors 9
Satish K Pillai
Vitalant Research Institute, USA University of California san francisco
Career Start Year 2001
Number of shared co-authors 3
Amy C Sims
The University of North Carolina at Chapel Hill
Career Start Year 1998
Number of shared co-authors 4
Viviana Simon
Icahn School of Medicine at Mount Sinai
Career Start Year 1997
Number of shared co-authors 13
Larissa B Thackray
Washington University School of Medicine
Career Start Year 1996
Number of shared co-authors 5
James D Chappell
Vanderbilt University Medical Center
Career Start Year 1995
Number of shared co-authors 5
Matthew B Frieman
Center for Pathogen Research, University of Maryland School of Medicine
Career Start Year 1993
Number of shared co-authors 11
Boyd L Yount
University of North Carolina at Chapel Hill
Career Start Year 1993
Number of shared co-authors 5
Melanie Ott
Gladstone Institute of Virology
Career Start Year 1993
Number of shared co-authors 12
Lucy Thorne
University College London
Career Start Year 1992
Number of shared co-authors 4
Keith R Jerome
Fred Hutchinson Cancer Center
Career Start Year 1991
Number of shared co-authors 18
Bart L Haagmans
Erasmus Medical Center
Career Start Year 1986
Number of shared co-authors 4

Collaborators

Akiko Iwasaki
Yale University
Co-authored papers 20
Nathan D Grubaugh
Yale School of Public Health
Co-authored papers 12
Albert I Ko
Instituto Goncalo Moniz, Yale School of Public Health
Co-authored papers 11
Benjamin Israelow
Yale University School of Medicine
Co-authored papers 11
Chantal B F Vogels
Yale School of Public Health
Co-authored papers 9
John G Doench
Co-authored papers 9
Eric Song
Yale University
Co-authored papers 8
Anna Marie Pyle
Yale University, USA Howard Hughes Medical Institute
Co-authored papers 7
Peiwen Lu
Yale University School of Medicine
Co-authored papers 7
Tianyang Mao
Yale University School of Medicine
Co-authored papers 6
Scott A Handley
Washington University School of Medicine
Co-authored papers 6
Aaron M Ring
Yale University School of Medicine
Co-authored papers 6
Shelli F Farhadian
Yale School of Medicine
Co-authored papers 6
Charles S Dela Cruz
Department of Microbial Pathogenesis Yale University New Haven
Co-authored papers 5
Brett D Lindenbach
Yale University School of Medicine
Co-authored papers 5
Beatrice H Hahn
Co-authored papers 5
David van Dijk
Yale School of Medicine, Yale University
Co-authored papers 5
Arnau Casanovas-Massana
School of Public Health, Yale University
Co-authored papers 5
Carolina Lucas
Yale School of Medicine
Co-authored papers 5
George M Shaw
Co-authored papers 5
Yuval Kluger
Yale University School of Medicine
Co-authored papers 4
Barton F Haynes
Co-authored papers 4
Stephanie Halene
Smilow Cancer Center, Yale University School of Medicine
Co-authored papers 4
Julie M Decker
Co-authored papers 4
Neal G Ravindra
Yale University School
Co-authored papers 4
Santos Bermejo
Yale University
Co-authored papers 4
Joseph R Fauver
University of Nebraska Medical Center
Co-authored papers 4
Anne L Wyllie
Yale School of Public Health
Co-authored papers 4
Benhur Lee
Icahn School of Medicine at Mount Sinai
Co-authored papers 4
Adam J Moore
Yale School of Public Health
Co-authored papers 3
Release 1.2